DAVID GRANOVSKY

Posts Tagged ‘heal’

SCIENTISTS “STUNNED” AS STROKE PATIENT WALKS AGAIN

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS FROM THE PAST, STEM CELLS IN THE NEWS on January 14, 2017 at 12:34 pm

“Stunned?”
C’mon guys…

stroke

STROKE CLINICAL TRIALS

  • The University of Texas, Health Science Center at Houston July 1, 2009       Several months after becoming the first patient in the United States to undergo a revolutionary new stroke treatment, Roland “Bud” Henrich continues to improve. Doctors intravenously injected Henrich, 61, with stem cells taken from his own bone marrow…”The stem cells, we believe, may help repair the damage to his brain caused by the stroke,” said Sean Savitz, M.D., assistant professor of neurology at The University of Texas Medical School at Houston and the study’s lead investigator. “Animal studies have shown that when you administer stem cells after stroke, the cells enhance the healing. We know that stem cells have some kind of guidance system and migrate to the area of injury. They’re not making new brain cells but they may be enhancing the repair processes and reducing inflammatory damage.” http://www.texmedctr.tmc.edu/root/en/TMCServices/News/2009/07-01/Stem+Cells+Tested+for+Treatment+of+Stroke.htm

Other STROKE articles:

  1. https://repairstemcell.wordpress.com/2010/09/21/autologous-neural-stem-cells-benefit-parkinson%e2%80%99s-patients-adultstemcell-com/
  2. https://repairstemcell.wordpress.com/2010/09/20/stem-cell-treatment-for-stroke-and-traumatic-brain-injury-wholewellness-net/
  3. http://www.scientificamerican.com/article.cfm?id=can-stem-cells-block-stroke-damage
  4. http://www.sciencedaily.com/releases/2011/08/110831160216.htm
  5. https://repairstemcell.wordpress.com/2010/04/28/stem-cells-from-menstrual-blood-may-benefit-stroke-patients/
  6. http://www.philly.com/philly/health/HealthDay686541_20140407_Stem_Cells_Show_Pro

—————-

New Stem Cell Treatment Leaves Scientists “Stunned” As Wheelchair-Bound Stroke Patient Walks Again

MORE THAN 70 PERCENT OF STROKE PATIENTS END UP WITH LONG-TERM DISABILITIES.

Researchers are said to be “stunned” by the success of a recent clinical trial of a new stem cell treatment for stroke patients. By injecting the cells into participants’ brains, scientists were able to produce some remarkable improvements, with several patients regaining motor function in their limbs.

A full report of the study has been published in the journal Stroke, with lead author Gary Steinberg telling the Washington Post that patients’ improvements were “not just minimal recovery like someone who couldn’t move a thumb now being able to wiggle it. It was much more meaningful. One 71-year-old wheelchair-bound patient was walking again.”

The trial involved the use of modified bone marrow–derived mesenchymal stem cells, which were injected into the specific region of each patient’s brain that had become damaged following their stroke. Amazingly, the researchers were not actually expecting to see any clinically relevant results at this stage, as they were just testing out a low dose of the treatment in order to assess its safety.

However, of the 18 patients involved in the study, seven experienced dramatic improvements in their cognitive and motor capabilities. In terms of safety, the study authors report that all participants experienced at least one temporary adverse effect, ranging from headaches and nausea to muscle spasticity. Importantly, though, all of these are thought to have been caused by the surgical procedure itself rather than the stem cells.

 

To evaluate the success of the treatment, the researchers used a number of standardized scales that are commonly used to assess the severity of symptoms in stroke patients. For instance, the Fugl-Meyer motor function total score is often used to measure recovery, with an improvement of 10 points representing a “clinically meaningful” change.

The patients involved in the study experienced an average improvement of 11.4 points on this scale, which translated into a “clinical improvement in the power of upper and lower limbs, ranging from an improvement in the ability to stand to the disappearance of tremor.”

Furthermore, the study authors make a point of noting that their patients had been suffering from their various symptoms for an average of 22 months prior to treatment. This is well beyond the six-month cut-off period that is typically considered to represent the point at which stroke-related brain damage becomes permanent and untreatable.

Exactly how the treatment works is not entirely understood, although Steinberg suspects that the stem cells somehow kick-start the brain’s own ability to repair itself, rather than developing into new neurons themselves.

Given that at present, more than 70 percent of people who suffer strokes end up with some sort of enduring disability, this new treatment could potentially be a game-changer – although more trials will be needed before it becomes readily available.

 

http://www.iflscience.com/brain/new-stem-cell-treatment-leaves-scientists-stunned-as-wheelchairbound-stroke-patient-walks-again/

Thomas Gray lived six days, but his life has lasting impact

In ALL ARTICLES, HOPE AND INSPIRATION on March 31, 2015 at 9:47 am

Thomas Gray lived six days, but his life has lasting impact

Sarah Gray reacts to research information about the donated retinas from her son, Thomas, who died at six days old in 2010. Callum, 5, Thomas´ identical twin brother, plays during the visit to the Hospital of the University of Pennsylvania.

Sarah Gray reacts to research information about the donated retinas from her son, Thomas, who died at six days old in 2010. Callum, 5, Thomas’ identical twin brother, plays during the visit to the Hospital of the University of Pennsylvania. DAVID MAIALETTI / Staff Photographer
Sarah Gray reacts to research information about the donated retinas from her son, Thomas, who died at six days old in 2010. Callum, 5, Thomas´ identical twin brother, plays during the visit to the Hospital of the University of Pennsylvania.
Gallery: Thomas Gray lived six days, but his life has lasting impact

Michael Vitez, INQUIRER STAFF WRITER

When she found out early in her pregnancy that one of her identical twins would die at birth, Sarah Gray began a five-year journey that culminated last week in Philadelphia.

She had to carry the sick baby to term in order to protect his healthy twin. And she also looked into organ and tissue donation.

“Instead of thinking of our son as a victim,” she said, “I started thinking of him as a contributor to research, to science.”

On March 23, 2010, Thomas and Callum Gray were born at Fairfax Hospital in Virginia. Callum, perfect, was five pounds, 10 ounces. Thomas, four pounds, was born without part of his brain. His mother nursed him, diapered him, cradled him.

He died after six days – five years ago on Sunday. Within hours of Thomas’ death, his eyes and liver were recovered and sent – along with umbilical cord blood from him and his brother – to researchers.But that wasn’t the end of it for Sarah Gray.

She often wondered – what became of his eyes, his blood, his liver?

The Grays had received a thank-you letter from the Washington regional transplant organization, telling them their son’s corneas had been sent to the Schepens Eye Research Institute in Boston, and his liver and the cord blood to Duke University in North Carolina.

Two years later, on a business trip to Boston, Sarah Gray called the eye institute, which is affiliated with Harvard Medical School.

“I donated my son’s eyes to your lab,” she said on the phone. “Can I come by for a tour?”

The receptionist said she had never had such a request. “I’m not sure who to transfer you to,” she said, “but don’t hang up!”

The next day, Gray met James Zieske, the institute’s senior scientist, who told her “infant eyes are worth their weight in gold,” because, being so young, they have great regenerative properties. Thomas’ corneas were used in a study that could one day help cure corneal blindness.

Thirteen more studies had cited that study. Gray felt a new emotion: pride.

Before leaving, she bought a Harvard T-shirt for Callum, and decided she was going to go with the whole family to North Carolina, where Thomas’ liver and the cord blood had been sent.

Zieske also wrote her: “Your visit helped to remind me that all the eyes we receive are an incredibly generous gift from someone who loved and cared about the person who provided the eyes. I thank you for reminding me of this.”

A few months later in 2012, the Grays went to the Duke Center for Human Genetics in Durham, N.C., where even though the twins were identical, scientists found epigenetic differences in their cord blood, research that could one day help prevent Thomas’ fatal defect, anencephaly.

Sarah Gray bought Callum a Duke T-shirt.

The couple then drove down to the road to visit Cytonet, a biotech company that had used their baby’s liver in a trial to determine the best temperature to freeze liver tissue.

Already in the nonprofit public relations field, Sarah Gray became director of marketing for the American Association of Tissue Banks.

Her mantra has become donate, donate, donate, and not just for transplant, but also for research. Even if nobody asks you – doctors are often uncomfortable when a child is dying – bring it up yourself, she says.

At a conference last summer, by coincidence, Gray learned that the Old Dominion Eye Bank in North Chesterfield, Va., had shipped Thomas’ retinas to Philadelphia.

She couldn’t believe she’d never known this. She immediately wrote to the researcher at the University of Pennsylvania who used the donation in her efforts to cure retinoblastoma, the most common form of eye cancer in children.

Two days later, Gray got a reply from Arupa Ganguly, who runs the lab and is a genetics professor at the Hospital of the University of Pennsylvania.

“It is almost impossible to obtain normal retina from a child,” Ganguly wrote. “The sample from Thomas is extremely precious for us.”

Ganguly sent Callum a Penn T-shirt.

They arranged to meet last Monday.

First, Sarah, Ross, and Callum Gray went to the National Disease Research Interchange in Center City, which Sarah Gray calls “the Match.com of science.” The interchange connects hospitals that supply organs and tissue with researchers who request it.

“This seems to have brought you a lot of peace and joy,” Bill Leinweber, the interchange’s president and CEO, told Sarah. “You’ve been such a strong advocate for research and such an eloquent spokesperson for the value of research.”

After a visit there, the Gray family went to Penn to meet Ganguly and tour her lab.

Sarah Gray saw the marbled composition book in which the receipt of retinas was logged on March 30, 2010, the 360th specimen to be received. They became “RES 360,” short for Research 360.

“Is this the log book?” she asked. “Oh, my gosh.”

Gray ran her index finger over the cursive of Jennifer Yutz, the lab manager who recorded the entry.

“Ross, look at this! Med 360!”

Her husband took a look. Callum, then 4, hugged an inflatable Godzilla as tall as he is, a gift from Ganguly, bouncing it on the lab floor.

“Wow,” Sarah Gray continued. “Can I Xerox this?”

“We have a copy for you,” Ganguly said.

Penn also gave the Grays a copy of the Fed Ex packing slip confirming arrival, which Sarah Gray said she would “treasure like a war medal.”

Thomas’ retina tissue is so rare, so precious, Ganguly and her team are still saving some of it for future research. Ganguly’s staff led Sarah Gray into the hallway, where a refrigerator, innocuous and ordinary, stood across from student lockers. Yutz unlocked it.

Inside were hundreds of 1.5 milliliter tubes – smaller than cigarette filters.

Yutz pointed to two.

“There it is,” Yutz said.

“Oh my gosh!” Gray said. She couldn’t touch them. The tubes were frozen at minus-80 degrees centigrade (minus-112 Fahrenheit).

“It’s the RNA isolated from the retina tissue,” Yutz said.

Call it what you will, that was a piece of Thomas Gray, her son.

Ross Gray has long supported his wife’s journey.

“It helped her get over the loss,” he said. “It was part of the healing process, seeing that there’s still research going on five years after. His life was worthwhile. He’s brought a lot of good to the world.”

“The way I see it,” Sarah Gray said, “our son got into Harvard, Duke, and Penn. He has a job. He is relevant to the world. I only hope my life can be as relevant.”

Read more at http://www.philly.com/philly/health/20150329_Thomas_Gray_lived_six_days__but_his_life_has_lasting_impact.html#ASIBfjvkMHBMos7Y.99

Anecdotal – The Dirty Word in Gordie Howe’s Stem Cell Treatment

In ALL ARTICLES on February 10, 2015 at 7:35 pm

What does it tell you when expert after expert tries to discredit the results of Gordie Howe’s stem cell treatment while his son Dr. Murray Howe, chairman of Toledo Hospital’s department of radiology, credits the stem cells for his recovery?

Dr. Murray Howe is the chairman of Toledo Hospital's department of radiology.

Dr. Murray Howe is the chairman of Toledo Hospital’s department of radiology.

What does it tell you when expert after expert claim his recovery and improvements are insignificant…while simultaneously attributing his recovery and improvements to everything except the stem cells he received?

What does it tell you when expert after expert discredits the anecdotal evidence of Gordie Howe’s recovery as “merely anecdotal” while it is actually one mere drop in an ocean of tens of thousands per year who have improved from cancer with cellular therapies over the last 59 years and tens of thousands who have improved over the past 12-14 years from non-cancer conditions?

And what is the value of this huge array of empirical and anecdotal evidence?

Gordie Howe Recovers From Stroke with Stem Cells

Gordie Howe Recovers From Stroke with Stem Cells

There are many types of evidence, not just trials or anecdotal.  Too often we reduce the evidential options to either clinical trials or anecdote.  Wrong.  That’s 5 blind men describing an elephant all over again.  We must take into account ALL of the different types of evidence and only THEN we can make a judgment based on the cumulative evidential data.

Anecdotal Evidence – Peyton Manning, Kobe Bryant, Rafael Nadar, Bartolo Colon…athletes from major sports organizations all over the world are embracing and anecdotally illustrating the safety and efficacy of cellular therapies

Statistical Evidence – 50,000 patients per year… are statistically illustrating the safety and efficacy of cellular therapies

Testimonial Evidence – Youtube is chock full of testimonies of athletes and patients who are benefiting from cellular therapies and via testimonial, illustrating the safety and efficacy of cellular therapies

Analogical Evidence – 59 years and thousands of trials and studies are analogously illustrating the safety and efficacy of cellular therapies

Clinical Trial evidence – Even though it may be the wrong process to evaluate cellular therapies, the vast majority of over 2,400 clinical trials are scientifically and empirically illustrating the safety and efficacy of cellular therapies

Miracle results? No.  This is par for the course results from real expectations based on the multitude of evidence types collected over the past six decades for cellular therapies.  The combined patchwork of all of the data from all of these evidences paints a very compelling conclusion.

Are cellular therapies safe and effective?  All of the evidences seem to say so.  Not just the anecdotal evidence;
anecdotal,
statistical,
testimonial,
analogical
and clinical trial evidences.

by David Granovsky, Stem Cell Writer and Author

Read one of the many myopically evidential articles here: http://www.theglobeandmail.com/globe-debate/the-stem-cell-miracle-is-anecdotal/article22880977/

SHOULD STEM CELLS BE USED ONLY AS A LAST RESORT?

In ALL ARTICLES on January 12, 2015 at 1:49 pm

https://i2.wp.com/upload.wikimedia.org/wikipedia/commons/e/e8/Last_Resort_Logo_Noir.png

Should stem cells be used only as a last resort? 

Two reasons why the answer is NO!

1.  Last week I saw someone with no education on stem cells stating that stem cells should be used only as a last resort.
The presentation of stem cell therapies as a last resort is tragic. Unfortunately, most people do come to me asking for information as a last resort.  They have been advised by their friends, family, medical professionals and media that they should try everything else and not try stem cells.  When all else fails and they finally approach me, “I’ve tried everything,” is a common explanation. Again, tragic. In many cases, the sooner stem cells are used, the faster patients can improve their quality of life, relieve their suffering and mediate their symptoms.
The CEO of a well known stem cell company made this analogy: “Most people renovate their homes just before selling them.  What a missed opportunity!  If they renovated them earlier they would derive years of pleasure from the renovation instead of fixing things up for the next owner.”  But what if you used stem cell therapies to improve your health and fix your body BEFORE you exhausted all other resources, money, energy, your immune system and your health?   What a concept.
2.  A new study is investigating the question: Is stem cell therapy less effective in older patients with chronic diseases?
Let’s over-simplify…
When was the last time a piece of equipment in your car failed and another one didn’t fail soon after.  This is because they are dependent upon each other for optimum efficiency.  The older the patient and the more advanced their disease, the odds are, the more there are other organs and systems being taxed beyond their capabilities.  And many people believe one pill will fix their disease but it’s far from true.  We must change the one pill for one one disease, one size fits all, magic cure belief which is rampant in the USA.  There is no evidence to support it.
Look at it another way.  Consider your body a battleground and the disease is the enemy.  The surest way to fight the enemy is to send wave after wave of soldiers (stem cells) into battle.  But many of the same issues in battle restrict maximizing the success of your therapy.  If you cut off the supply routes to the soldiers carrying food and ammunition (a weakened or restricted circulatory system), your soldiers’ ability to move to the battle will be ineffective.  If you wipe out their communications (cytokines/messenger cells), your soldiers won’t know where to go or what is needed to fight.
Time is always against us.  The longer we wait, the more our resources will be depleted and our other organs and systems will be taxed, both to support the failing areas and due to the natural deterioration associated with aging.  “Aging and chronic diseases including CVD and diabetes substantially affect stem/progenitor cells of adult organism. Such conditions could restrict the effectiveness of autologous cell therapy in aged patients with CAD, lower limb ischemia, T2DM and other chronic pathologies, although these patients are some of the most obvious candidates for cell therapy.”

Autologous Stem Cell Therapy: How Aging and Chronic Diseases Affect Stem and Progenitor Cells – http://online.liebertpub.com/doi/full/10.1089/biores.2014.0042

It is my hope that people do real research or talk to someone who has so they can make an educated decision about reclaiming their health. There is a great deal of misinformation out there and many people are trying to sabotage the real info and data getting to those whom need it most. Let’s work together to get rid of misinformation and not perpetuate the confusion which may lead to unnecessary suffering.  DON’T WAIT.

LORI MILLS WINS BATTLE WITH BLUE CROSS IN WAR ON CIDP

In ALL ARTICLES, BUSINESS OF STEM CELLS, STEM CELLS IN THE NEWS, VICTORIES & SUCCESS STORIES on January 9, 2015 at 8:08 pm

“A journey of a thousand miles begins with a single step.”Lao-tzu,

Lori Mills’ story is now mainstream and may affect millions of people in years to come.  You may have seen her in the dictionary under “persistence” or next to the quote: “be the change you want to see in the world.”  Certainly she is a very lucky woman.  Or maybe it’s simpler than that.  Maybe she is simply a mother and a wife who wants to live her life as best as she can without simultaneously carrying the burden of a debilitating illness.

Lori has chronic inflammatory demyelinating polyneuropathy or CIDP and she was denied insurance coverage by Blue Cross Blue Shield in the Summer of 2014.  One week ago, believe it or not, they reversed their decision. This is a huge victory for Lori in the battle with Blue Cross Blue Shield.  This is also the first of many skirmishes in her war on CIDP and a minor victory for those that follow her.  Here’s how it breaks down:

  • Be excited for Lori as she now has a chance at a better life.  She has defeated the one thing standing in her way of getting treated.
  • Don’t expect insurance companies to start caving tomorrow as BCBS has already stated with conviction that this is not to be seen as a precedent.
  • The treatment she is approved for is a clinical trial with exclusionary criteria, not from a treatment center so this is not available to the general public.

I reached out to Lori today and both she and her friends responded with grace and respect:

Hi Lori,
I’m following your story with great interest. I am a 10 year stem cell educator and while Blue Cross is clear in stating that this shouldn’t be considered precedent setting I just wanted to personally thank you for your hard work to get the doors open just a little bit more for those people who are suffering needlessly with conventional drug and treatment protocols which do not work for them. Kudos to you and yours! Wishing you the best,
David

We wish her great success and hope to do a follow up on her progress at the end of her trial.

————————-

I’d like to share something with you.  Look at the image below.  It jumped out at me.
A simple statement.  “I’m a CIDP Fighter.”
We can all understand what it means to fight a single adversary.
With awareness and education we can learn what it means to fight an invisible neurological illness like CIDP.
And that should be enough.  For anyone.  But it isn’t.

Today’s patients seek answers, seek cures, seek stem cell therapies…
but they are not just fighting their conditions…
they often are simultaneously fighting the medical establishment, fighting insurance companies, fighting ignorance and fighting resistance.
It should not be this hard.  We should do more to make it easier for patients to get the treatments they need.  We must do more.

https://i2.wp.com/api.ning.com/files/g3sZFdca7acig06FeFWUZqdRPlquxI2mTDs9uAFPDyLXkzcpRZ7I43vUcRg17SeZXVckqdfYklRANSSUHPFwBNvR9VB6NnHt/603671_10102191952132385_769765818_n1.jpg

Blue Cross overturns decision, approves stem cell transplant coverage

GREENVILLE, Mich. — Lori Mills has been approved to receive a stem cell transplant under her Blue Cross Blue Shield coverage.

The insurance company has overturned its previous denial from the summer of 2014.

In a letter Mills received January 2, 2015, Blue Cross states the company will now pay for the potentially life-changing procedure.

“I know it’s going to be a shot at a whole new life for me,” Mills said today.

She added, “I know that because of our previous interview, it really helped get this approval letter because whenever I call they talk about it.”

FOX 17 also interviewed Mills in October, questioned Blue Cross, and aired her story.

She suffers from chronic inflammatory demyelinating polyneuropathy or CIDP. Her immune system attacks her nervous system. She shakes, has numbness, and it impairs her movement.

Doctors told her a stem cell transplant could be the cure.

via

RELATED ARTICLES:

NONMYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CIDP

http://www.neurology.org/content/69/18/1802.short

Haemopoietic stem cell transplantation—an evolving treatment for severe autoimmune and inflammatory diseases in rheumatology, neurology and gastroenterology

http://www.maneyonline.com/doi/abs/10.1080/10245330701255106

Autologous haemopoietic stem cell transplantation for autoimmune diseases
http://informahealthcare.com/doi/abs/10.1517/14712598.2011.580272

PROOF THE ENVIRONMENT CONTRIBUTES TO DISEASE

In ALL ARTICLES, DISEASE INFO, HEALTH AND WELLNESS on November 26, 2014 at 4:33 pm

Science has poo-pooed the effect of environmental toxins for years citing that the miniscule concentrations of toxins couldn’t possibly cause harm to the human body. Everything from GMOs to toxins in vaccines were ignored based on this premise. New science reveals though that the environment can not only effect the human body but it can change DNA and contribute to diseases. Now that there’s proof, it’s time to get the crap out of our lives. -David Granovsky toxin-problem HOW ENVIRONMENT CONTRIBUTES TO SEVERAL HUMAN DISEASES National Institute of Environmental Health Sciences (NIEHS) Using a new imaging technique, researchers have found that the biological machinery that builds DNA can insert molecules into the DNA strand that are damaged as a result of environmental exposures. These damaged molecules trigger cell death that produces some human diseases, according to the researchers. The work provides a possible explanation for how one type of DNA damage may lead to cancer, diabetes, hypertension, cardiovascular and lung disease, and Alzheimer’s disease… Samuel Wilson, M.D., senior NIEHS researcher on the team, explained that the damage is caused by oxidative stress, or the generation of free oxygen molecules, in response to environmental factors, such as ultraviolet exposure, diet, and chemical compounds in paints, plastics, and other consumer products… “When one of these oxidized nucleotides is placed into the DNA strand, it can’t pair with the opposing nucleotide as usual, which leaves a gap in the DNA,” Wilson said. “Until this paper, no one had actually seen how the polymerase did it or understood the downstream implications.” http://www.niehs.nih.gov/news/newsroom/releases/2014/november25/index.cfm http://www.sciencedaily.com/releases/2014/11/141125101703.htm

LATE STAGE OVARIAN CANCER CURED WITH STEM CELLS

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS, VICTORIES & SUCCESS STORIES on July 7, 2014 at 1:03 pm

ovarian-cancer-symptoms
Hue Hospital Succeeds in Treating Cancer with Stem Cell

Saigon – Doctors of Hue Central Hospital have used stem cell transplantation to successfully treat a cancer patient of the last stage. The Hue Central Hospital announced on June 26 that its doctors have cured Le Thi Sau, 52, who was suffering ovarian cancer in the last stage, with stem cell transplant. The operation is the success of the scientific project “Using stem cell in breast cancer and cervical cancer” managed by Professor Nguyen Duy Thang, deputy head of the hospital. Adult stem cells have been used to treat certain cancers through bone marrow transplants. In this therapy, the stem cells that give rise to the different blood cells in the body are transplanted into the bone marrow of the patient, where they regenerate the blood. The project was given green light to carry out in the Hue Central Hospital by the Ministry of Science and Technology. Professor Nguyen Duy Thang said the success of this method will pave the way for next operations on breast and ovarian cancer patients. In the time ahead, the hospital continues to treat two other cancer female patients with the stem cell treatment. It is hoped that the treatment will save many cancer patients. (www.saigon-gpdaily.com.vn June 27)

WHAT DOES THE FOXO1 SAY? HERE’S MORE INSULIN!

In ALL ARTICLES, BUSINESS OF STEM CELLS on July 5, 2014 at 10:20 am
It May Take Guts to Cure Diabetes -Human GI Cells Retrained to Produce Insulin

Imagine taking cells from your gastrointestinal tract and then switching off one gene, the FOXO1 gene, and then ending up with insulin producing cells.  From gut cell to diabetes fighter in one easy gene switch-off.  Scientists did this successfully in 2012 in mice and recently in humans.  What does the FOXO1 say? ‘Here’s more insulin!’  Awesome.

The next step is where it gets…awkward.  I’d like this information to generate a gene therapy protocol or to improve success rates in stem cell/Diabetes treatment protocols,  etc.  But that’s not the way our system works.  The next step is to find a drug that inhibits the FOXO1 gene so it “…could retrain cells inside a person’s GI tract to produce insulin…”  Unfortunately, this drug will also have side effects as all drugs do which will create other symptoms requiring other drugs to mitigate.  And so it goes.

When will US Diabetes patients be able to benefit from a medical protocol based on this discovery?  An educated guess puts it at:
7-10 years for clinical trials and drug development for a name brand Pharma product and then 10-15 years for the drug patent to open up to an affordable generic.
Sorry Diabetes patients.

New York, NY (June 30, 2014) “By switching off a single gene, scientists at Columbia University’s Naomi Berrie Diabetes Center have converted human gastrointestinal cells into insulin-producing cells, demonstrating in principle that a drug could retrain cells inside a person’s GI tract to produce insulin…The Columbia researchers were able to teach human gut cells to make insulin in response to physiological circumstances by deactivating the cells’ FOXO1 gene.”

STEM CELLS HIT MAIN STREAM MEDIA!

In ALL ARTICLES, STEM CELLS IN THE NEWS, VICTORIES & SUCCESS STORIES on June 27, 2014 at 9:03 pm

STEM CELLS HIT MAIN STREAM MEDIA! 
On NBC tonight at 8pm EST!

The first stem cell generated windpipe was implanted in 2008.
Six long years later, the technique has been improved significantly and has hit main stream media. 

Image

“Macchiarini’s team began by collecting stem cells from Beyene’s bone marrow. Those cells were mixed with special growth factors and then poured onto a scaffold made from plastic — in fact, the very same plastic that is used to make soda bottles — which had been made to mimic the shape of a real windpipe.  In just a matter of days, the scaffold began to transform into an actual functioning windpipe.”

Some attack those pushing the boundaries, citing that the surgery is experimental and unproven.  But the Dr can’t stand by as patients die when he can do something about it and can’t ignore their pleas for a chance at the hope of recovery.  This is cutting edge of medicine and there are thousands of clinical trials and studies and 10s to 100s of thousands of patients treated, most outside of the US.  There are no guarantees.  There are always risks, even with rigorously tested pharmaceutical drugs and treatment protocols that have been used for decades.  But for chronic and terminal patients who are given no chance for recovery, experimental sounds like a pretty great option.

Historically, new treatments have always been met with resistance.

“Tom Starzl, when he started doing liver transplants, the first seven, eight, nine patients all died. Everybody said he was nuts, OK? Christian Barnard, when he started doing heart transplants, everyone threw rocks at him. This is how we’re going to treat diseases in the future and this is the start of it.”

Anything which pushes the envelop of contemporary knowledge will be rejected by those clinging to traditional concepts…but without pioneering doctors and even more pioneering patients, willing to take risks, medical protocols can not advance.  I salute the doctor and the patients who are the ground-breaking pioneers in the new land of regenerative medicine.  And what can their mutual risk do for the patient and millions to follow?

“One of Macchiarini’s most promising success stories is Claudia Castillo, a Spanish mother who is doing so well six years after her transplant that an increasing number of Macchiarini’s colleagues are beginning to see him in a new light.”

Thank you!

To watch the video and learn more:

http://www.nbcnews.com/health/health-news/leap-faith-desperate-patients-look-lab-grown-organs-n142036

PANCREATIC CANCER TUMORS DEFEATED WITH CORD BLOOD STEM CELLS

In ALL ARTICLES, SCIENCE & STEM CELLS, VICTORIES & SUCCESS STORIES on June 25, 2014 at 11:42 am

fight pancreatic cancer FPC_shirt


PANCREATIC CANCER TUMORS DEFEATED WITH CORD BLOOD STEM CELLS

What happens when you “genetically engineer MSCs isolated from human umbilical cord blood so that they expressed IL-15” (which fights cancer tumors) and inject them into mice with pancreatic  tumors?

  • The IL-15 migrate to the tumor
  • Other cancer and tumor fighting immune cells migrate to the tumor
  • The IL-15 attack the tumor
  • Other cancer and tumor fighting immune cells attack the tumor
  • Tumors show cell death
  • Tumor growth is significantly inhibited
  • Survival is prolonged
  • The mice immune systems are effectively vaccinated against future tumor growth

Scientists “used these souped-up cells to treat In mice afflicted with pancreatic tumors. Pancreatic cancer is an indiscriminate killer, since by the time it causes any symptoms, it is usually so advanced, that there is little to be done in order to treat it. Thus new strategies to treat this type of cancer are eagerly being sought. Systemic administration of IL-15-expressing MSCs significantly inhibited tumor growth and prolonged the survival of tumor-bearing mice. The tumors of these mice showed extensive cell death, and other types of immune cells known to fight tumor cells (NK and T cells) had also accumulated around the tumor. Other experiments confirmed that the injected MSCs did indeed migrate toward the tumors and secrete IL-15 at the site of the tumors…Interestingly, those mice that were cured from the pancreatic tumors, appeared to have a kind of resistance of these tumors. Namely, when Fan and his colleagues tried to reintroduce the same tumor cells back into the cured mice, the tumor cells would not grow. Thus the engineered MSCs not only tuned the immune system against the tumor, but they effectively vaccinated the mice against it as well.”

via http://beyondthedish.wordpress.com/2014/06/23/engineered-stem-cels-from-human-umbilical-cord-blood-eradicates-pancreatic-tumor/

 

 

Thanks Squeeky!

mouse-grown-from-stem-cells

%d bloggers like this: